1110 ECP CatalYm
BioCentury & Getty Images

Emerging Company Profile

CatalYm: opening up tumors to immune cells

Emerging Company Profile: German start-up targets GDF15’s immunosuppressant function to enable immune cell infiltration to tumors

Berlin-based CatalYm aims to resensitize cancer cells to checkpoint inhibitors by targeting GDF15, which restores the ability of immune cells to infiltrate the tumor.

Nov 11, 2020 | 12:15 AM GMT

CatalYm is targeting a lesser known immunosuppressant function of GDF15 to resensitize cancer patients to checkpoint blockade and enhance the ability of CAR T therapies to infiltrate solid tumors.

The Munich-based biotech has raised €50 million ($58.2 million) in a series B round led by Vesalius Biocapital III

Read the full 1059 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE